Compare MCFT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | CRDF |
|---|---|---|
| Founded | 1968 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 329.0M | 130.7M |
| IPO Year | 2015 | 2012 |
| Metric | MCFT | CRDF |
|---|---|---|
| Price | $20.94 | $1.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $22.25 | $9.63 |
| AVG Volume (30 Days) | 144.0K | ★ 663.1K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $284,203,000.00 | $365,993.00 |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $56.00 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $14.42 | $1.48 |
| 52 Week High | $26.49 | $4.56 |
| Indicator | MCFT | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 37.59 |
| Support Level | $18.86 | $1.51 |
| Resistance Level | $21.20 | $2.05 |
| Average True Range (ATR) | 0.71 | 0.11 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 62.69 | 2.99 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.